However, the outlook for patients with CLL has improved dramatically with therapies that directly target components of the BCR signaling pathway,5 particularly Bruton tyrosine kinase (Btk), or apoptosis through targeting the Bcl-2 protein. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.